United States
Germany
Japan
United Kingdom
China
Posts for 6/2023
Breaking News: FDA Approves ELEVIDYS™ as First Gene Therapy for Duchenne Muscular Dystrophy!
Jun 27, 2023
On June 22nd, 2023, the FDA provided accelerated approval for ELEVIDYS™, the first gene therapy to treat Duchenne Muscular Dystrophy (DMD)2. DMD is a genetic disorder that results in progressive muscle degeneration due to altered expression of the protein dystrophin, which is responsible for strengthening muscle fibers and facilitating safe muscle contractions1,4. Without proper dystrophin expression, muscle cells become fragile and easily damaged. The symptom...
Lentiviral Vectors as Catalysts for Vaccine Development
Jun 16, 2023
In the ever-evolving landscape of genetic research, lentiviral gene delivery has emerged as a powerful tool that has revolutionized the field of gene therapy and vaccine development. Lentiviral vectors (LVs), derived from HIV-1, have gained significant attention due to their unique ability to efficiently and stably transfer genetic material into both dividing and non-dividing cells. Particularly in the realms of infectious diseases and immuno-oncology, lentiviral...
Lentiviral Vectors as Catalysts for Vaccines
Jun 16, 2023
In the ever-evolving landscape of genetic research, lentiviral gene delivery has emerged as a powerful tool that has revolutionized the field of gene therapy and vaccine development. Lentiviral vectors (LVs), derived from HIV-1, have gained significant attention due to their unique ability to efficiently and stably transfer genetic material into both dividing and non-dividing cells. Particularly in the realms of infectious diseases and immuno-oncology, lentiviral...
